Chemotherapy Plus Pembrolizumab After Progression With Previous PD-1/PD-L1 Inhibitors in Patients With Advanced Non-small Cell Lung Cancer: Placebo-controlled Randomized Phase II Study
Latest Information Update: 08 Feb 2022
At a glance
- Drugs Pembrolizumab (Primary) ; Docetaxel; Pemetrexed; Vinorelbine
- Indications Carcinoma; Non-small cell lung cancer
- Focus Therapeutic Use
- 31 Jan 2022 Primary endpoint of Progression-free survival (PFS)(At the median follow-up duration of 10.5 months) has not been met as per Results published in the Clinical Cancer Research
- 31 Jan 2022 Results published in the Clinical Cancer Research
- 09 Jun 2019 Status changed from not yet recruiting to recruiting.